Drugs / MG98
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003890 | Feb 1999 → Sep 2001 | cancer of unknown primary site | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG98 | “MG98, a phosphorothioate antisense oligodeoxynucleotide that is a specific inhibitor of mRNA for human DNA methyltransferase 1 (DNMT1), was evaluated in a phase I study.” PMID 12702532 ↗ May 2003 |
| Action | Inhibit | “specific inhibitor of mRNA for human DNA methyltransferase 1 (DNMT1)” PMID 12702532 ↗ May 2003 |
| Modality | Antisense oligonucleotide | “MG98, a phosphorothioate antisense oligodeoxynucleotide” PMID 12702532 ↗ May 2003 |
| Route | Intravenous | “MG98 was given as a 2 h i.v. infusion twice weekly three weeks out of every four” PMID 12702532 ↗ May 2003 |
| Target | DNMT1 | “specific inhibitor of mRNA for human DNA methyltransferase 1 (DNMT1)” PMID 12702532 ↗ May 2003 |